Posts tagged CLDX


Company Update (NASDAQ:CLDX): Celldex Therapeutics, Inc. Presents Data on CDX-1140 at the American Society of Hematology Annual Meeting

Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented data on new product candidate CDX-1140, a fully human antibody …

Stock Update (NASDAQ:CLDX): Celldex Therapeutics, Inc. Completes Acquisition of Kolltan Pharmaceuticals

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today it has completed its previously announced acquisition of Kolltan …

Stock Update (NASDAQ:CLDX): Celldex Therapeutics, Inc. Presents Data on New Product Candidate, CDX-1140

Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented data on new product candidate CDX-1140, a fully human antibody …

Roth Capital Reiterates Buy on Celldex Therapeutics, Inc. (CLDX) Following 3Q:16 Results; Shares Rose 14%

In a research report published Tuesday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Celldex …

Stock Update (NASDAQ:CLDX): Celldex Therapeutics, Inc. Announces Acquisition of Kolltan Pharmaceuticals

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that the Company has entered into a definitive agreement to acquire …

Brean Capital Assumes Buy on Celldex Therapeutics, Inc. (CLDX); Sees 265% Upside for the Stock

Brean Capital analyst Jason Wittes was out with a research report, assuming coverage on shares of Celldex Therapeutics, Inc. …

Company Update (NASDAQ:CLDX): Celldex Therapeutics, Inc. Names Elizabeth Crowley as Chief Product Development Officer

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that the Company has promoted Elizabeth Crowley to the newly created …

Company Update (NASDAQ:CLDX): Celldex Therapeutics, Inc. Reports Second Quarter 2016 Results

Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported business and financial highlights for the second quarter ended June 30, …

Show More